

UC Davis

UC Davis Previously Published Works

Title

L. pneumophila CMP-5,7-di- N -acetyllegionaminic acid synthetase (LpCLS)-involved chemoenzymatic synthesis of sialosides and analogues

Permalink

<https://escholarship.org/uc/item/92c5z8b5>

Journal

Organic & Biomolecular Chemistry, 18(4)

ISSN

1477-0520

Authors

McArthur, John B
Santra, Abhishek
Li, Wanqing
et al.

Publication Date

2020-01-28

DOI

10.1039/c9ob02476j

Peer reviewed



Published in final edited form as:

Org Biomol Chem. 2020 January 28; 18(4): 738–744. doi:10.1039/c9ob02476j.

***L. pneumophila* CMP-5,7-di-*N*-acetyllegionaminic acid synthetase (LpCLS)-involved chemoenzymatic synthesis of sialosides and analogues†**

John B. McArthur, Abhishek Santra[#], Wanqing Li, Anoopjit S. Kooner, Ziqi Liu[‡], Hai Yu, Xi Chen


Department of Chemistry, University of California, One Shields Avenue, Davis, CA 95616, USA.

Abstract

5,7-Di-*N*-acetyllegionaminic acid (Leg5,7Ac₂) is a bacterial nonulosonic acid (NuIO) analogue of sialic acids, an important class of monosaccharides in mammals and in some bacteria. To develop efficient one-pot multienzyme (OPME) glycosylation systems for synthesizing Leg5,7Ac₂-glycosides, *Legionella pneumophila* cytidine 5'-monophosphate (CMP)-Leg5,7Ac₂ synthetase (LpCLS) was cloned and characterized. It was successfully used in producing Leg5,7Ac₂-glycosides from chemoenzymatically synthesized Leg5,7Ac₂ using a one-pot two-enzyme system or from its chemically synthesized six-carbon monosaccharide precursor 2,4-diacetamido-2,4,6-trideoxymannose (6deoxyMan2,4diNAc) in a one-pot three-enzyme system. In addition, LpCLS was shown to tolerate Neu5Ac7NAc, a C9-hydroxyl analogue of Leg5,7Ac₂ and also a stable analogue of 7-*O*-acetylneuraminic acid (Neu5,7Ac₂), to allow OPME synthesis of the corresponding α-3-linked sialosides, from chemically synthesized six-carbon monosaccharide precursor 4-*N*-acetyl-4-deoxy-*N*-acetylmannosamine (ManNAc7NAc).

Graphica Abstract

A bacterial CMP-5,7-di-*N*-acetyllegionaminic acid synthetase was characterized and used in one-pot multienzyme systems for efficient synthesis of Leg5,7Ac₂-glycosides and analogs.



†Electronic Supplementary Information (ESI) available: pH profiles and donor substrate promiscuity studies of PmST1 P34H/M144L. ¹H and ¹³C NMR spectra for Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcβProN₃ (Neu5Acα2-6LNnTβProN₃) and Neu5Acα2-6Galβ1-4GlcNAcβ1-3(Neu5Acα2-6)Galβ1-4GlcβProN₃. See DOI: 10.1039/x0xx00000x

xiichen@ucdavis.edu; Fax: +1 530 752-8995; Tel: +1 530 754-6037.

[#]Current address: Polymers and Functional Materials Division, CSIR-Indian Institute of Chemical Technology (IICT), Uppal Road, Tarnaka, Hyderabad-500 007, India

[‡]Current Address: Department of Chemical Biology, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China

Introduction

One-pot multienzyme (OPME) glycosylation systems¹ enable efficient synthesis of naturally occurring and non-natural carbohydrate structures from suitable glycosyltransferase acceptors and simple monosaccharides or derivatives in the presence of one or more nucleoside 5'-triphosphates (NTPs). The scope of OPME products is broad due to substrate promiscuity of enzymes used but it can also be restricted by the lack of access to enzymes with desired substrate tolerance. Here we report the expansion of our collection of sugar nucleotide biosynthetic enzymes and the development of OPME systems with improved efficiency for chemoenzymatic synthesis of 5,7-di-*N*-acetyllegionaminic acid (Leg5,7Ac₂)-containing glycosides and their analogues.

Leg5,7Ac₂ (**1**) (Figure 1) is a bacterial nonulosonic acid (NulO or nine-carbon α -keto acid) structurally similar to the most common sialic acid form, *N*-acetylneuraminic acid (Neu5Ac, **2**), which decorates the non-reducing ends of many human glycoprotein N- and O-linked glycans, glycolipids, and oligosaccharides.² Leg5,7Ac₂ (**1**) differs from Neu5Ac (**2**) only at C7 and C9 where Leg5,7Ac₂ lacks a C9-hydroxyl group in Neu5Ac and has a second *N*-acetyl group in place of Neu5Ac C7-hydroxyl group.^{2, 3} Leg5,7Ac₂ has been found on cell surface glycoconjugates of various bacterial pathogens, such as homo- and heteropolymeric lipopolysaccharides (LPS),^{4, 5} capsular polysaccharides,⁶ and flagella glycoproteins.⁷ These include the lipopolysaccharide of *Legionella pneumophila* serogroup 1, the causative parasite of Legionnaires' disease.⁴

The biological roles and associated fitness advantages of Leg5,7Ac₂ expression in pathogenic bacteria are largely unknown.⁸ It was suggested that these Leg5,7Ac₂ motifs on cell surface structures help pathogens evade host immunity by mimicking Neu5Ac.^{9, 10} However, microarray-conjugated Leg5,7Ac₂ analysis with pooled human sera revealed the presence of anti-Leg5,7Ac₂ immunoglobulin G (IgG) antibodies, indicating that the monosaccharide moiety is recognizable by the human immune system and that serum donors likely encountered pathogens displaying Leg5,7Ac₂-containing epitopes.¹¹ On the other hand, an analogue of human glycosphingolipid GD1a with its terminal sialic acid replaced by Leg5,7Ac₂ was rendered unrecognizable by Siglec-4.¹² Terminal α 2-3- and α 2-6-linked Leg5,7Ac₂ is highly resistant to cleavage by human sialidase NEU2,^{13, 14} though it is unclear if this property applies to other human sialidases or if it is relevant to pathogenicity.¹³

Though the C9-deoxy modification of Neu5Ac in Leg5,7Ac₂ is foreign for human glycans, the C7 *N*-acetyl modification of Neu5Ac in 7-acetamido-7-deoxy-*N*-acetylneuraminic acid (Neu5Ac7NAc, **3**) (Figure 1) is isosteric to its C7 *O*-acetyl modification naturally found on some mammalian and bacterial sialic acids.¹⁵⁻¹⁷ In fact, a 9-*N*-acetyl analogue (Neu5Ac9NAc) of 9-*O*-acetyl Neu5Ac (Neu5,9Ac₂) has been used as a stable mimic for functional studies.^{18, 19} Such a strategy could be particularly valuable for 7-*O*-acetyl Neu5Ac (Neu5,7Ac₂), since sialic acid 7-*O*-acetyl modification is known to spontaneously migrate to its C9 hydroxyl group.²⁰ The functional importance of C7 and C9 *O*-acetyl modifications might be elucidated by testing individual modifications separately which is only feasible by using more stable structural analogues of Neu5,7Ac₂-glycosides such as

those containing the corresponding *N*-acetyl group. In addition, Neu5Ac7NAc (**3**) can be considered as a C9-OH analogue of Leg5,7Ac₂ (**1**). Comparing the functions of glycosides containing these two monosaccharide counterparts will help to elucidate the role of C9-deoxy modification in Leg5,7Ac₂. Native biosynthetic pathways of forming Leg5,7Ac₂-glycosides⁹ do not allow the access to their analogues with individual 7-OH²¹ or C9-hydroxyl modification on Leg5,7Ac₂. Chemoenzymatic synthesis, on the other hand, can be an efficient strategy to overcome the challenges to access the desired derivatives.

Synthetic oligosaccharides containing Leg5,7Ac₂ or its analogues could elucidate pathogen-host interaction mechanisms and contribute to the discovery of novel therapeutic or diagnostic tools. Recently, we improved the synthesis of Leg5,7Ac₂ and Leg5,7Ac₂-glycosides which were either un-accessed previously or synthesized in low yields through biological or synthetic approaches.¹⁴ In that strategy, a diazido mannose analogue, 2,4-diazido-2,4,6-trideoxymannose (6deoxyMan2,4diN₃), was designed and synthesized as a chemoenzymatic synthon for producing Leg5,7Ac₂-glycosides using OPME systems containing a sialic acid aldolase, *Neisseria meningitidis* CMP-sialic acid synthetase (NmCSS), and a bacterial α2-3- or α2-6-sialyltransferase.¹⁴ As NmCSS^{22, 23} was unable to catalyze the synthesis of CMP-Leg5,7Ac₂ directly from Leg5,7Ac₂ and cytidine-5'-triphosphate (CTP), Leg5,7diN₃-glycosides were produced in OPME reactions. Subsequent conversion of the azido groups of Leg5,7diN₃-containing glycosides to acetamido groups using thioacetic acid in a saturated sodium bicarbonate aqueous solution led to the formation of desired Leg5,7Ac₂-glycosides.¹⁴ To further simplify the procedures for the synthesis, we explore the application of a bacterial cytidine 5'-monophosphate-5,7-di-*N*-acetyllegionaminic acid (CMP-Leg5,7Ac₂) synthetase (CLS) in OPME glycosylation systems for efficient synthesis of desired Leg5,7Ac₂-glycosides and their analogues containing Neu5Ac7NAc, the C9-hydroxyl analogue of Leg5,7Ac₂.

Results and discussion

We identified *Legionella pneumophila* CMP-Leg5,7Ac₂ synthetase (LpCLS)²⁴ as a well suited candidate for the OPME synthesis of Leg5,7Ac₂-glycosides and analogues. It was previously cloned, expressed, purified, tested for activity,²⁴ and used in synthetic reactions.¹³ It catalyzes the formation of cytidine 5'-monosaccharide (CMP)-Leg5,7Ac₂ (**6**) from Leg5,7Ac₂ (**1**) and cytidine 5'-triphosphate (CTP) in the presence of a divalent metal cation such as Mg²⁺ (Scheme 1).^{3, 9} Its biochemical characterization, however, was limited due to lack of access to a sufficient amount of Leg5,7Ac₂.

To enable more detailed characterization, C-terminal hexahistidine (His₆)-tagged LpCLS was expressed recombinantly in *E. coli* BL21(DE) cells from a pET-22b(+) plasmid. Shaking flask expression followed by purification using an immobilized nickel-nitrilotriacetic acid (Ni²⁺-NTA) affinity column yielded 38 mg of pure enzyme per liter culture. The enzyme was shown to require a divalent metal cation such as Mg²⁺ (as shown in previous reports^{3, 9}) or Mn²⁺, but not Ca²⁺ or monovalent metal cation Na⁺, for activity (Figure S1). Addition of ethylenediaminetetraacetic acid (EDTA) completely abolished the enzyme activity. The absence of activity with NaCl or EDTA further confirms that the enzyme activity is dependent on the presence of a divalent cation. The pH-profile of LpCLS

(Figure S2) showed that its activity was optimal at pH 8.5 and 88% of its activity was retained at pH 9.0. A dramatic loss of activity was observed when the pH was at or below 7.0 or at or above 9.5. The activity was completely lost at pH 6.0 or lower under the experimental conditions. Low LpCLS activity was detected at alkaline conditions when pH reached as high as 11.0. This tolerance toward alkaline conditions and loss of activity at acidic conditions should be taken into consideration when optimizing conditions for LpCLS-involved OPME systems.

It was previously reported that LpCLS was highly sensitive to CTP concentrations, with CTP concentrations above 1.0 mM or below 0.5 causing severe decline in product formation.¹³ This was not observed in our experiments. However, during LpCLS kinetics characterization, apparent substrate inhibition was observed when varying Leg5,7Ac₂ concentration to above 1.0 mM with a CTP concentration fixed at 2.0 mM. This effect confirms an ordered mechanism similar to that illustrated for NmCSS²⁵ in which CTP must bind first. When varying CTP concentrations with a fixed Leg5,7Ac₂ concentration of 2 mM, LpCLS was found to have a k_{cat} of $28.4 \pm 2.0 \text{ s}^{-1}$, K_M of $1.1 \pm 0.2 \text{ mM}$, and k_{cat}/K_M of $26 \text{ s}^{-1} \text{ mM}^{-1}$. These values were comparable to those of NmCSS towards CTP in the presence of Neu5Ac (1 mM)²³ with a k_{cat} of $21 \pm 1 \text{ s}^{-1}$, K_M of $0.59 \pm 0.10 \text{ mM}$, and k_{cat}/K_M of $36 \text{ s}^{-1} \text{ mM}^{-1}$. These results suggested that LpCLS would be a well suited catalyst for OPME glycosylation systems.

Indeed, LpCLS was successfully used in a one-pot two-enzyme (OP2E) glycosylation system containing *Pasteurella multocida* α 2–3-sialyltransferase 1 (PmST1)²⁶ as the glycosyltransferase for the synthesis of Leg5,7Ac₂ α 2–3Gal β 1–4GlcNAc β ProN₃ (**8**) from previously chemoenzymatically synthesized Leg5,7Ac₂ (**1**),¹⁴ CTP, and Gal β 1–4GlcNAc β ProN₃ (or LacNAc β ProN₃, **7**)²⁷ with an excellent 93% yield (Scheme 2). In this system, CMP-Leg5,7Ac₂ (**6**) was generated *in situ* from Leg5,7Ac₂ (**1**) and CTP, and used directly in PmST1-catalyzed synthesis of Leg5,7Ac₂-glycoside (**8**) in the same reaction mixture. The formation of the α -linkage in nonulosonic acid glycoside **8** was supported by ¹H NMR signals at δ 2.79 (dd, $J = 12.5, 4.5 \text{ Hz}$, 1H, H-3_{eq}) and 1.76 (t, $J = 12.1 \text{ Hz}$, 1H, H-3_{ax}). Small-scale assays showed that PmST1 M144D,²⁸ a mutant of PmST1 with decreased sialidase and donor hydrolysis activities, was similarly efficient as PmST1 for the OP2E synthesis of Leg5,7Ac₂-glycosides.

To further demonstrate the application of LpCLS in efficient synthesis of Leg5,7Ac₂-containing glycosides, a one-pot three-enzyme (OP3E) system was tested. If successful, the system would allow the efficient synthesis of Leg5,7Ac₂-glycans directly from 6deoxyManNAc4NAc (**4**), the six-carbon precursor of Leg5,7Ac₂ (**1**).¹⁴ As shown in Scheme 3, *Pasteurella multocida* sialic acid aldolase (PmAldolase)²⁹ was able to catalyze the synthesis of **1** from **4** and sodium pyruvate.¹⁴ The **1** formed *in situ* was activated by LpCLS and transferred to a galactoside Gal β 1–3GalNAc β ProN₃ (**9**)³⁰ by PmST1 M144D²⁸ for the formation of the desired glycoside Leg5,7Ac₂ α 2–3Gal β 1–3GalNAc β ProN₃ (**10**) in 82% yield without the need for isolating intermediates Leg5,7Ac₂ (**1**) and CMP-Leg5,7Ac₂ (**6**). ¹H NMR signals at δ 2.78 (dd, $J = 12.0, 4.8 \text{ Hz}$, 1H, H-3_{eq}) and 1.73 (t, $J = 12.0 \text{ Hz}$, 1H, H-3_{ax}) confirm the formation of the α -linkage in nonulosonic acid glycoside **10**. It is worth to note that Leg5,7Ac₂ α 2–3Gal β 1–3GalNAc β OR which has the same trisaccharide structure

in **10** is a trisaccharide component of the tetrasaccharide repeat of *Enterobacter cloacae* C6285 O-antigen.⁵

LpCLS was also used in the OP3E system described above for the synthesis of sialosides containing Neu5Ac7NAc (**3**), a C9-hydroxyl-analogue of Leg5,7Ac₂ (**1**) and also a 7-*N*-acetyl-analogue of Neu5,7Ac₂ (Scheme 4). To produce Neu5Ac7NAc-glycosides, 4-*N*-acetyl-4-deoxy-*N*-acetylmannosamine (ManNAc4NAc, **5**) was chemically synthesized from ManNAc4N₃ (**11**)³¹ in 70% yield using thioacetic acid in pyridine. The obtained **5** was readily converted by PmAldolase to form Neu5Ac7NAc (**3**), which was activated by LpCLS to form CMP-Neu5Ac7NAc (**12**) to be used as the donor substrate for PmST1 for the formation of two α 2–3-linked Neu5Ac7NAc-containing glycoside analogues Neu5Ac7NAc α 2–3LacNAc β ProN₃ (**14**, 71% yield) and Neu5Ac7NAc α 2–3Lac β ProN₃ (**15**, 74% yield) from their corresponding galactosides LacNAc β ProN₃ (**7**)²⁷ and Lac β ProN₃ (**13**),²⁶ respectively. ¹H NMR signals at δ 2.80 (dd, J = 12.5, 4.5 Hz, 1H, H-3_{eq}) and 1.77 (t, J = 12.0 Hz, 1H, H-3_{ax}) for compound **14** and at δ 2.80 (dd, J = 12.5, 4.5 Hz, 1H, H-3_{eq}), 1.77 (t, J = 12.1 Hz, 1H, H-3_{ax}) for compound **15** confirm the formation of the α -linkage in the corresponding nonulosonic acid glycosides.

Conclusions

With chemoenzymatically synthesized Leg5,7Ac₂ (**1**) in hand, recombinant LpCLS was biochemically characterized in more details. It was also shown to be a well-suited component for one-pot multienzyme (OPME) glycosylation systems for highly efficient synthesis of not only Leg5,7Ac₂-glycosides but also their analogues containing C9-hydroxyl derivative of Leg5,7Ac₂.

Experimental Section

Materials and methods

Chemicals were purchased and used as received. NMR spectra were recorded in the NMR facility of the University of California, Davis, on a Bruker Avance-800 NMR spectrometer. Chemical shifts are reported in parts per million (ppm) on the δ scale. High resolution (HR) electrospray ionization (ESI) mass spectra were obtained using a Thermo Electron LTQ-Orbitrap Hybrid MS at the Mass Spectrometry Facility in the University of California, Davis. The *Legionella pneumophila legF* gene was codon optimized, synthesized, and cloned between the NdeI and SalI sites of pET-22b(+) commercially by Biomatik (See Figures S4 and S5 in ESI for DNA and protein sequences). Leg5,7Ac₂ (**1**),¹⁴ 6deoxyManNAc4NAc (**4**),¹⁴ Gal β 1–4GlcNAc β ProN₃ (or LacNAc β ProN₃, **7**),²⁷ Gal β 1–3GalNAc β ProN₃ (**9**),³⁰ ManNAc4N₃ (**11**),³¹ Gal β 1–4Glc β ProN₃ (or Lac β ProN₃, **13**)²⁶ were synthesized as reported previously.

Overexpression and purification

Flasks containing 1 L of autoclaved LB media supplemented with ampicillin (0.1 mg mL⁻¹) were inoculated with 1 mL of overnight cultured *E. coli* BL21(DE3) cells harboring the plasmid. The 1 L cultures were grown at 37 °C until OD₆₀₀ reached 0.6 to 1.0, then

expression was induced with isopropyl β -D-1-thiogalactoside (IPTG) to a final concentration of 1 mM and the cells shaken at 20 °C overnight. Cells were harvested by centrifugation at $5000 \times g$ for 20 minutes, resuspended in 20 mL of Tris-HCl (pH 7.5, 100 mM) and lysed by sonication with the following method: amplitude at 65%, 10 s pulse on and 30 s pulse off for 18 cycles. The lysate was collected after centrifugation at 8000 pm for 30 minutes and then loaded onto a Ni^{2+} -NTA affinity column at 4 °C that was pre-equilibrated with 6 column volumes of binding buffer (50 mM Tris-HCl buffer, pH 7.5, 10 mM imidazole, 0.5 M NaCl). The column was washed with 10 column volumes of binding buffer and 10 column volumes of washing buffer (50 mM of Tris-HCl buffer, pH 7.5, 50 mM of imidazole, 0.5 M of NaCl) sequentially to wash away the nonspecific binding protein. The target protein was eluted using Tris-HCl buffer (50 mM, pH 7.5) containing imidazole (200 mM) and NaCl (0.5 M). Fractions containing the purified protein were combined and 50% glycerol was added to a final concentration of 10% glycerol. LpCLS was stored at -20 °C. From 1 L culture, 38 mg of pure LpCLS was isolated.

UHPLC analysis method

Metal ion effects, pH profile, and kinetic analysis were quantified with an Infinity 1290-II UHPLC equipped with a UV-Vis detector (Agilent Technologies, CA) and a ZORBAX Eclipse Plus C18 Rapid Resolution HD 1.8 μm particle 2.1×50 mm column (Agilent Technologies, CA). Separation of CMP-Leg5,7Ac₂ from CTP used the following method with 10 mM tetrabutylammonium hydroxide pH 4.5 as eluent A and acetonitrile as eluent B: 4% B for 3 minutes, 4% to 60% B over 10 minutes, 1 minute at 95% B, and 2 minutes at 4% B. Reactions were monitored at 280 nm.

Metal ion effects

Reactions were performed in duplicate at 37 °C for 30 minutes with Tris-HCl (100 mM, pH 8.0), various metal salts (10 mM), CTP (1 mM), Leg5,7Ac₂ (1 mM), and LpCLS (14 nM). Reactions were stopped by heat denaturation at 70 °C for 10 minutes. The mixtures were chilled at 4 °C and centrifuged at $18,500 \times g$ for 5 minutes. Supernatants were analyzed by the UHPLC analysis method as described above.

pH Profile

Reactions were performed in duplicate at 37 °C for 30 minutes in a solution containing MgCl_2 (10 mM), CTP (1 mM), Leg5,7Ac₂ (1 mM), and LpCLS (28 nM) with MES buffer (100 mM) for pH values between 4.5 and 6.5 or Tris-HCl buffer (100 mM) for pH values between 7.0 and 9.0, and CAPS buffer (100 mM) for pH values between 9.5 and 11.0. Reactions were stopped by heat denaturation at 70 °C for 10 minutes. The mixtures were chilled at 4 °C and centrifuged at $18,500 \times g$ for 5 minutes. Supernatants were analyzed with the UHPLC analysis method as described above.

Kinetics

Reactions were performed in duplicate at 37 °C for 30 minutes with Tris-HCl (100 mM, pH 8.5), MgCl_2 (10 mM), LpCLS (1.4 nM with varied CTP concentrations, 0.7 nM with varied Leg5,7Ac₂ concentrations), varying concentrations (0.2, 0.5, 1.0, 2.0, and 5.0 mM) of the

variable substrate, and 2 mM of the other substrate. Reactions were stopped by heat denaturation at 70 °C for 10 minutes. The mixtures were chilled at 4 °C and centrifuged at 18,500 × g for 5 minutes. Supernatants were analyzed with the UHPLC analysis method as described above. Kinetic parameters for reactions with a fixed concentration (2 mM) of Leg5,7Ac₂ and varying CTP concentrations were determined in GraFit 5.0 by non-linear regression.

One-pot two-enzyme (OP2E) synthesis of Leg5,7Ac₂α2–3LacNAcβProN₃ (8) from Leg5,7Ac₂ (1) and LacNAcβProN₃ (7)

LacNAcβProN₃ (24 mg, 10 mM) and Leg5,7Ac₂ (1.2 equiv.) were incubated at 30 °C in Tris-HCl buffer (100 mM, pH 8.5) containing CTP (1.8 equiv.), MgCl₂ (20 mM), LpCLS (2 mg), and PmST1 (3 mg). The reaction was monitored by thin-layer chromatography (TLC) using a developing solvent consisting of EtOAc:MeOH:H₂O = 5:2:1 (by volume) and the TLC plates were stained with a *p*-anisaldehyde sugar stain. After being incubated at 30 °C for 12 h, the reaction was quenched by adding the same volume of pre-chilled ethanol and the reaction mixture was centrifuged to remove precipitates. The supernatant was concentrated and passed through a BioGel P-2 gel filtration column eluting with water followed by a C18 column (H₂O:CH₃CN = 1:0 to 4:1, by volume) to obtain the product Leg5,7Ac₂α2–3LacNAcβProN₃ (8) (37.4 mg, Yield 93%, white foam). ¹H NMR (400 MHz, D₂O) δ 4.58–4.50 (m, 2H, Gal-1-H and GlcNAc-1H), 4.12 (dd, *J* = 9.9, 3.1 Hz, 1H), 4.05–3.93 (m, 4H), 3.89–3.79 (m, 3H), 3.77–3.68 (m, 8H), 3.64–3.55 (m, 3H), 3.39 (t, *J* = 6.7 Hz, 2H), 2.79 (dd, *J* = 12.5, 4.5 Hz, 1H, H-3_{eq} of Leg5,7Ac₂), 2.06 (s, 3H), 1.99 (s, 3H), 1.95 (s, 3H), 1.85 (p, *J* = 6.4 Hz, 2H), 1.76 (t, *J* = 12.1 Hz, 1H, H-3_{ax} of Leg5,7Ac₂), 1.17 (d, *J* = 6.2 Hz, 3H, H-9 of Leg5,7Ac₂). ¹³C NMR (100 MHz, D₂O) δ 174.47, 173.97, 173.95, 173.70, 102.58, 101.12, 99.51, 78.42, 75.35, 75.11, 74.72, 72.36, 71.80, 69.40, 68.72, 67.12, 66.90, 60.99, 60.27, 60.08, 55.06, 53.87, 52.01, 47.76, 40.08, 28.09, 22.15, 22.12, 21.92, 18.07. HRMS (ESI-Orbitrap) *m/z*: [M – H][–] Calcd for C₃₀H₄₉N₆O₁₈ 781.3109; found 781.3108.

One-pot three-enzyme (OP3E) synthesis of Leg5,7Ac₂-containing glycan Leg5,7Ac₂α2–3Galβ1–3GalNAcβProN₃ (10) from 6deoxyMan2,6diNAc₂ (4) and Galβ1–3GalNAcβProN₃ (9)

Galβ1–3GalNAcβProN₃ (9)³⁰ (50 mg, 10 mM), 6deoxyManNAc4NAc (4)¹⁴ (1.5 equiv.), sodium pyruvate (7.5 equiv.), CTP (1.8 equiv.) were dissolved in water in a 50 mL centrifuge tube containing Tris-HCl buffer (100 mM, pH 8.5) and MgCl₂ (20 mM). After adding PmAldolase (1.7 mg), LpCLS (0.8 mg), and PmST1 M144D (1.2 mg) water was added to bring the final volume to 11 mL. The reaction mixture was incubated at 30 °C for 16 h. The reaction progress was monitored using TLC (EtOAc:MeOH:H₂O = 6:2:1, by volume) and mass spectrometry. The reaction mixture was diluted with the same volume of chilled ethanol and incubated at 4 °C for 30 min. The mixture was then centrifuged and supernatant was concentrated and purified by a Bio-Gel P-2 gel column (water was used as an eluent). Then the product containing fractions were concentrated and was further purified by C18 column (CH₃CN in H₂O gradient was used as running solvents) to produce Leg5,7Ac₂α2–3Galβ1–3GalNAcβProN₃ (10) (68 mg, 82%). ¹H NMR (800 MHz, D₂O) δ 4.50 (d, *J* = 8.8 Hz, 1H, GalNAc-1H), 4.47 (d, *J* = 7.2 Hz, 1H, Gal-1H), 4.16 (d, *J* = 2.4 Hz, 1H), 4.08–4.01 (m, 2H), 4.01–3.94 (m, 2H), 3.91 (d, *J* = 3.2 Hz, 1H), 3.88 (dd, *J* = 10.4, 2.4 Hz, 1H), 3.86–3.78 (m, 3H), 3.78–3.66 (m, 6H), 3.62–3.54 (m, 3H), 3.39–3.37 (m, 2H), 2.78 (dd, *J* = 12.0,

4.8 Hz, 1H, H-3_{eq} of Leg5,7Ac₂), 2.03 (s, 3H), 1.98 (s, 3H), 1.94 (s, 3H), 1.88–1.81 (m, 2H), 1.73 (t, *J* = 12.0 Hz, 1H, H-3_{ax} of Leg5,7Ac₂), 1.14 (d, *J* = 6.4 Hz, 3H, H-9 of Leg5,7Ac₂). ¹³C NMR (200 MHz, D₂O) δ 174.10, 173.47, 173.36, 173.27, 104.26, 100.88, 98.92, 79.10, 75.11, 74.41, 74.30, 71.18, 68.37, 68.20, 67.54, 66.88, 66.55, 66.41, 60.51, 60.45, 53.45, 51.44, 50.84, 47.32, 39.73, 27.63, 21.76, 21.63, 21.44, 17.60. HRMS (ESI-Orbitrap) *m/z*: [M – H][–] Calcd for C₃₀H₄₉N₆O₁₈ 781.3109; found 781.2995.

Chemical synthesis of ManNAc4NAc (5) from ManNAc4N₃ (11)

To produce ManNAc4NAc (5), ManNAc4N₃ (11)³¹ (103.3 mg, 0.419 mmol) was dissolved in pyridine (8 mL) and thioacetic acid (2 mL) was added. The mixture was stirred at room temperature for 16 h and then concentrated *in vacuo*. The crude product was purified by column chromatography (ethyl acetate:MeOH = 10:1, by volume) to produce 77 mg (70%) of ManNAc4NAc (5, a mixture of α and β anomers) as a white solid. ¹H NMR (800 MHz, D₂O) δ 5.14 (bs, 0.6H), 4.97 (bs, 0.4H), 4.45 (d, *J* = 4.8 Hz, 0.4H), 4.30 (d, *J* = 4.8 Hz, 0.6H), 4.10 (dd, *J* = 10.8, 4.0 Hz, 0.6H), 3.76–3.99 (m, 2H), 3.52–3.74 (m, 2H), 3.39–3.47 (m, 0.4H), 1.97–2.31 (m, 6H). ¹³C NMR (200 MHz, D₂O) δ = 175.7, 174.8, 174.7, 174.6, 92.9, 92.8, 75.3, 70.8, 69.9, 66.6, 60.6, 60.5, 53.4, 52.4, 48.1, 47.8, 21.9, 21.8. HRMS (ESI-Orbitrap) *m/z*: [M + Na]⁺ calcd for C₁₀H₁₈N₂O₆Na 285.1057; found 285.1058.

OP3E chemoenzymatic synthesis of Neu5Ac7NAc-glycosides Neu5Ac7NAcα2–3LacNAcβProN₃ (14) and Neu5Ac7NAcα2–3LacβProN₃ (15) from chemically synthesized ManNAc4NAc (5)

An acceptor 7 or 13 (10 mM) and ManNAc4NAc (5) (1.2 equiv.) were incubated at 30 °C in Tris-HCl buffer (100 mM, pH 8.5) containing sodium pyruvate (6.0 equiv.), CTP (1.8 equiv.), MgCl₂ (20 mM), an appropriate amount of PmAldolase (10 mg), LpCLS (5 mg), and PmST1 (4 mg). The reaction was monitored by thin-layer chromatography (TLC) using a developing solvent consisting of EtOAc:MeOH:H₂O = 5:2:1 (by volume) and the TLC plates were stained with a p-anisaldehyde sugar stain. After being incubated at 30 °C for 72 h, the reaction was quenched by adding the same volume of pre-chilled ethanol and the reaction mixture was centrifuged to remove precipitates. The supernatant was concentrated and passed through a BioGel P-2 gel filtration column eluting with water followed by a C18 column (H₂O:CH₃CN = 1:0 to 4:1) to obtain the target products.

Neu5Ac7NAcα2–3LacNAcβProN₃ (14) Yield 71%; 60 mg, White foam. ¹H NMR (400 MHz, D₂O) δ 4.60–4.49 (m, 2H, Glc-1H and Gal-1H), 4.14 (dd, *J* = 10.4, 2.9 Hz, 1H), 4.06–3.94 (m, 4H), 3.94–3.47 (m, 16H), 3.39 (t, *J* = 6.7 Hz, 2H), 2.80 (dd, *J* = 12.5, 4.5 Hz, 1H, H-3_{eq} of Neu5Ac7NAc), 2.06 (s, 3H), 1.99 (s, 3H), 1.95 (s, 3H), 1.85 (p, *J* = 6.3 Hz, 2H), 1.77 (t, *J* = 12.0 Hz, 1H, H-3_{ax} of Neu5Ac7NAc). ¹³C NMR (100 MHz, D₂O) δ 174.47, 174.00, 173.88, 173.82, 102.54, 101.12, 99.53, 78.39, 75.42, 75.11, 74.71, 72.34, 71.85, 71.62, 69.42, 68.64, 67.12, 66.94, 62.42, 61.00, 60.10, 55.07, 51.86, 49.18, 47.76, 40.10, 28.09, 22.15, 22.10, 21.85. HRMS (ESI-Orbitrap) *m/z*: [M – H][–] Calcd for C₃₀H₄₉N₆O₁₉ 797.3058; found 797.3032.

Neu5Ac7NAcα2–3LacβProN₃ (15) Yield 74%; 65 mg, white foam. ¹H NMR (400 MHz, D₂O) δ 4.54 (d, *J* = 7.9 Hz, 1H), 4.50 (d, *J* = 8.0 Hz, 1H), 4.14 (dd, *J* = 9.6, 2.0 Hz, 1H),

4.05–3.94 (m, 4H), 3.94–3.87 (m, 1H), 3.87–3.43 (m, 16H), 3.33 (t, $J = 8.3$ Hz, 1H), 2.80 (dd, $J = 12.5, 4.5$ Hz, 1H, H-3_{eq} of Neu5Ac7NAc), 2.08–1.85 (m, 8H), 1.77 (t, $J = 12.1$ Hz, 1H, H-3_{ax} of Neu5Ac7NAc). ¹³C NMR (100 MHz, D₂O) δ 174.00, 173.88, 173.83, 102.61, 102.12, 99.51, 78.30, 75.44, 75.12, 74.73, 74.35, 72.78, 71.84, 71.63, 69.40, 68.64, 67.35, 66.93, 62.42, 61.00, 60.11, 51.86, 49.17, 47.86, 40.12, 28.22, 22.10, 21.84. HRMS (ESI-Orbitrap) m/z : [M – H][–] Calcd for C₂₈H₄₆N₅O₁₉ 756.2792; found 756.2762.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by United States National Institutes of Health (NIH) grant R01AI130684. Bruker Avance-800 NMR spectrometer was funded by United States National Science Foundation grant DBI-0722538.

Notes and references

1. Li W, McArthur JB and Chen X, Carbohydr. Res, 2019, 472, 86–97. [PubMed: 30529493]
2. Chen X and Varki A, ACS Chem. Biol, 2010, 5, 163–176. [PubMed: 20020717]
3. Schoenhofen IC, Young NM and Gilbert M, Methods Enzymol, 2017, 597, 187–207. [PubMed: 28935102]
4. Knirel YA, Rietschel ET, Marre R and Zahringer U, Eur. J. Biochem, 1994, 221, 239–245. [PubMed: 8168511]
5. Filatov AV, Wang M, Wang W, Perepelov AV, Shashkov AS, Wang L and Knirel YA, Carbohydr. Res, 2014, 392, 21–24. [PubMed: 24837902]
6. Shashkov AS, Kenyon JJ, Senchenkova SN, Shneider MM, Popova AV, Arbatsky NP, Miroshnikov KA, Volozhantsev NV, Hall RM and Knirel YA, Glycobiology, 2016, 26, 501–508. [PubMed: 26711304]
7. Logan SM, Hui JP, Vinogradov E, Aubry AJ, Melanson JE, Kelly JF, Nothaft H and Soo EC, FEBS J, 2009, 276, 1014–1023. [PubMed: 19154343]
8. Andolina G, Wei R, Liu H, Zhang Q, Yang X, Cao H, Chen S, Yan A, Li XD and Li X, ACS Chem. Biol, 2018, 13, 3030–3037. [PubMed: 30230814]
9. Schoenhofen IC, Vinogradov E, Whitfield DM, Brisson JR and Logan SM, Glycobiology, 2009, 19, 715–725. [PubMed: 19282391]
10. Tomek MB, Janesch B, Maresch D, Windwarder M, Altmann F, Messner P and Schaffer C, Glycobiology, 2017, 27, 555–567. [PubMed: 28334934]
11. Matthies S, Stallforth P and Seeberger PH, J. Am. Chem. Soc, 2015, 137, 2848–2851. [PubMed: 25668389]
12. Watson DC, Wakarchuk WW, Gervais C, Durocher Y, Robotham A, Fernandes SM, Schnaar RL, Young NM and Gilbert M, Glycoconj. J, 2015, 32, 729–734. [PubMed: 26452603]
13. Watson DC, Leclerc S, Wakarchuk WW and Young NM, Glycobiology, 2011, 21, 99–108. [PubMed: 20978010]
14. Santra A, Xiao A, Yu H, Li W, Li Y, Ngo L, McArthur JB and Chen X, Angew. Chem. Int. Ed. Engl, 2018, 57, 2929–2933. [PubMed: 29349857]
15. Butor C, Diaz S and Varki A, J. Biol. Chem, 1993, 268, 10197–10206. [PubMed: 8486687]
16. Wipfler D, Srinivasan GV, Sadick H, Kniep B, Arming S, Willhauck-Fleckenstein M, Vlasak R, Schauer R and Schwartz-Albiez R, Glycobiology, 2011, 21, 1161–1172. [PubMed: 21507905]
17. Gurung MK, Raeder IL, Altermark B and Smalas AO, Glycobiology, 2013, 23, 806–819. [PubMed: 23481098]
18. Khedri Z, Xiao A, Yu H, Landig CS, Li W, Diaz S, Wasik BR, Parrish CR, Wang LP, Varki A and Chen X, ACS Chem. Biol, 2017, 12, 214–224. [PubMed: 27936566]

19. Li W, Xiao A, Li Y, Yu H and Chen X, *Carbohydr. Res.*, 2017, 451, 51–58. [PubMed: 28961426]
20. Kamerling JP, Schauer R, Shukla AK, Stoll S, Van Halbeek H and Vliegenthart JF, *Eur. J. Biochem.*, 1987, 162, 601–607. [PubMed: 3830159]
21. Khedri Z, Muthana MM, Li Y, Muthana SM, Yu H, Cao H and Chen X, *Chem. Commun.*, 2012, 48, 3357–3359.
22. Yu H, Yu H, Karpel R and Chen X, *Bioorg. Med. Chem.*, 2004, 12, 6427–6435. [PubMed: 15556760]
23. Li Y, Yu H, Cao H, Muthana S and Chen X, *Appl. Microbiol. Biotechnol.*, 2012, 93, 2411–2423. [PubMed: 21968653]
24. Glaze PA, Watson DC, Young NM and Tanner ME, *Biochemistry*, 2008, 47, 3272–3282. [PubMed: 18275154]
25. Matthews MM, McArthur JB, Li Y, Yu H, Chen X and Fisher AJ, *Biochemistry*, 2019, DOI: 10.1021/acs.biochem.9b00517.
26. Yu H, Chokhawala H, Karpel R, Yu H, Wu B, Zhang J, Zhang Y, Jia Q and Chen X, *J. Am. Chem. Soc.*, 2005, 127, 17618–17619. [PubMed: 16351087]
27. Lau K, Thon V, Yu H, Ding L, Chen Y, Muthana MM, Wong D, Huang R and Chen X, *Chem. Commun.*, 2010, 46, 6066–6068.
28. Sugiarto G, Lau K, Qu J, Li Y, Lim S, Mu S, Ames JB, Fisher AJ and Chen X, *ACS Chem. Biol.*, 2012, 7, 1232–1240. [PubMed: 22583967]
29. Li Y, Yu H, Cao H, Lau K, Muthana S, Tiwari VK, Son B and Chen X, *Appl. Microbiol. Biotechnol.*, 2008, 79, 963–970. [PubMed: 18521592]
30. Yu H, Thon V, Lau K, Cai L, Chen Y, Mu S, Li Y, Wang PG and Chen X, *Chem. Commun.*, 2010, 46, 7507–7509.
31. Khedri Z, Li Y, Muthana S, Muthana MM, Hsiao CW, Yu H and Chen X, *Carbohydr. Res.*, 2014, 389, 100–111. [PubMed: 24680514]







Figure 1. Structures of 5,7-di-*N*-acetyllegionaminic acid (Leg5,7Ac₂, **1**), *N*-acetylneuraminic acid (Neu5Ac, **2**) which is the most abundant sialic acid form in nature, 7-acetamido-7-deoxy-*N*-acetylneuraminic acid (Neu5Ac7NAc, **3**), 2,4-diacetamido-2,4,6-trideoxy-D-mannose (6deoxyManNAc4NAc, **4**) which is the six-carbon biosynthetic precursor of Leg5,7Ac₂ (**1**), and 2,4-diacetamido-2,4-dideoxy-D-mannose (ManNAc4NAc, **5**) which is the six-carbon biosynthetic precursor of Neu5Ac7NAc (**3**).

**Scheme 1.**


LpCLS-catalyzed reaction for the formation of CMP-Leg5,7Ac₂ (**6**) from Leg5,7Ac₂ (**1**) and CTP in the presence of Mg²⁺.

**Scheme 2.**

LpCLS-catalyzed one-pot two-enzyme (OP2E) synthesis of Leg5,7Ac₂-containing glycan Leg5,7Ac₂α2-3Galβ1-4GlcNAcβProN₃ (8) from Leg5,7Ac₂ (1), Galβ1-4GlcNAcβProN₃ (7), and CTP.

**Scheme 3.**

LpCLS-catalyzed one-pot three-enzyme (OP3E) synthesis of Leg_{5,7}Ac₂-containing glycan Leg_{5,7}Ac₂α₂-3Galβ₁-3GalNAcβProN₃ (**10**) from 6deoxyMan_{2,6}diNAc₂ (**4**), sodium pyruvate, Galβ₁-3GalNAcβProN₃ (**9**), and CTP.

**Scheme 4.**

Chemical synthesis of ManNAc4NAc (**5**) from ManNAc4N₃ (**11**) and LpCLS-catalyzed one-pot three-enzyme (OP3E) synthesis of Neu5Ac7NAc-glycosides Neu5Ac7NAc-2-3LacNAcβProN₃ (**14**) and Neu5Ac7NAc-2-3LacβProN₃ (**15**) from LacNAcβProN₃ (**7**) and LacβProN₃ (**13**), respectively, in the presence of chemically synthesized ManNAc4NAc (**5**), sodium pyruvate, and CTP.